论文部分内容阅读
目的:评估检测血清IL-17在多发性骨髓瘤(MM)诊断、预后及疗效判断方面的应用价值。方法:ELISA法检测21例MM患者(初诊7例,复发9例,平稳期5例)和15名健康体检者的IL-17、VEGF、TNF-α和β2-m血清含量,并分析IL-17与VEGF、TNF-α和β2-m水平之间的相关性。结果:初诊及复发MM患者的IL-17、VEGF、TNF-α和β2-m水平显著高于平稳期MM患者和对照组,差异有统计学意义,P<0.05。平稳期MM患者与对照组之间差异无统计学意义,P>0.05。IL-17、VEGF、TNF-α和β2-m的血清水平随着临床分期的增加而呈增高趋势,且除了IL-17外,Ⅲ期MM患者的VEGF、TNF-α和β2-m的血清水平均显著高于Ⅱ期患者,Ⅱ期患者显著高于Ⅰ期患者,差异均有统计学意义,P<0.05;ⅢA期MM患者的IL-17水平虽高于ⅡB期MM患者,但差异无统计学意义,P>0.05。比较各期患者A和B亚型各因子水平差异发现,除β2-m外,其余因子水平均是B亚型显著高于A亚型,差异有统计学意义(P<0.05),而ⅢB期MM患者的β2-m水平虽高于ⅢA期MM患者,但差异无统计学意义,P>0.05。MM患者的IL-17水平与TNF-α(r=0.918)、VEGF(r=0.862)和β2-m(r=0.953)均呈正相关,P值均<0.01。结论:IL-17能够促进血管新生并与MM进展相关,可作为MM临床分期、预后及疗效判断的潜在指标。
Objective: To evaluate the value of detecting serum IL-17 in the diagnosis, prognosis and curative effect of multiple myeloma (MM). Methods: The serum levels of IL-17, VEGF, TNF-α and β2-m in 21 MM patients (7 newly diagnosed, 9 relapsed, 5 stable) and 15 healthy controls were detected by ELISA. The levels of IL- 17 and VEGF, TNF-α and β2-m levels. Results: The levels of IL-17, VEGF, TNF-α and β2-m in newly diagnosed and relapsed MM patients were significantly higher than those in stable MM patients and controls, with statistical significance (P <0.05). There was no significant difference between stable MM patients and control group (P> 0.05). Serum levels of IL-17, VEGF, TNF-α and β2-m tended to increase with the increase of clinical stage. Serum levels of VEGF, TNF-α and β2-m The levels of IL-17 in patients with stage IIA were higher than those in patients with stage IIB disease, but the difference was not statistically significant Statistical significance, P> 0.05. Comparing the different levels of A and B subtypes, we found that except for β2-m, the levels of other factors were significantly higher in subtype B than in subtype A, the difference was statistically significant (P <0.05) The level of β2-m in patients with MM was higher than that in patients with stage ⅢA MM, but the difference was not statistically significant (P> 0.05). The level of IL-17 in MM patients was positively correlated with TNF-α (r = 0.918), VEGF (r = 0.862) and β2-m (r = 0.953) Conclusion: IL-17 can promote angiogenesis and correlate with the progression of MM, which may be used as a potential indicator of clinical stage, prognosis and curative effect of MM.